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Elucidation of mechanisms that govern lipid storage, oxidative stress and insulin resistance may 
lead to improved therapeutic options for type 2 diabetes and other obesity-related diseases. Here, 
we find that adipose expression of the small neutral amino acid transporter SLC7A10, also known 
as alanine-serine-cysteine transporter 1 (ASC-1), shows strong inverse correlates with visceral 
adiposity, insulin resistance and adipocyte hypertrophy across multiple cohorts. Concordantly, loss 
of Slc7a10 function in zebrafish in vivo accelerates diet-induced body weight gain and adipocyte 
enlargement. Mechanistically, SLC7A10 inhibition in human and murine adipocytes decreases 
adipocyte serine uptake and total glutathione levels and promotes reactive oxygen species (ROS) 
generation. Conversely, SLC7A10 overexpression decreases ROS generation and increases 
mitochondrial respiratory capacity. RNA-sequencing revealed consistent changes in gene 
expression between human adipocytes and zebrafish visceral adipose tissue following loss of 
SLC7A10, e.g., upregulation of SCD (lipid storage) and downregulation of CPT1A (lipid 
oxidation). Interestingly, ROS scavenger reduced lipid accumulation and attenuated the lipid-
storing effect of SLC7A10 inhibition. These data uncover adipocyte SLC7A10 as a novel 
important regulator of adipocyte resilience to nutrient and oxidative stress, in part by enhancing 
glutathione levels and mitochondrial respiration, conducive to decreased ROS generation, lipid 
accumulation, adipocyte hypertrophy, insulin resistance and type 2 diabetes. 
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Adipocyte hypertrophy in both subcutaneous (SC) and visceral white adipose tissue (WAT) is 
strongly associated with whole-body insulin resistance, with or without obesity and adipose tissue 
(AT) inflammation (1,2), and with fatty liver, dyslipidemia, impaired mitochondrial function, and 
reduced insulin-stimulated glucose uptake in adipocytes (3). Experimental impairment of 
mitochondrial respiration and increased reactive oxygen species (ROS) generation in adipocytes 
reduces adipocyte insulin sensitivity (4), and the extent of mitochondrial dysfunction determines 
the severity of insulin resistance and type 2 diabetes (5). However, the molecular mechanisms that 
promote adipocyte hypertrophy and insulin resistance remain incompletely understood, and we 
urgently need new potential treatment targets.  
SLC7A10, also known as alanine-serine-cysteine transporter 1 (ASC-1),  has sodium-independent 
activity and high affinity for the small neutral amino acids (AAs) glycine, L-alanine, L-threonine, 
L-cysteine, L-serine and D-serine (6,7). SLC7A10 is highly expressed in certain regions of the 
brain, and is being explored as a therapeutic target in neuropsychiatric disorders (e.g., 
schizophrenia) (8). 
 
A previous report showed selective expression of SLC7A10 in white but not beige or brown 
adipocytes, with 5-fold higher expression in AT compared to the highest expressing parts of the 
brain, and diminished expression in other tissues (9). However, the possible role of SLC7A10 in 
metabolic regulation has not been explored. 
 
While AAs known to be transported by SLC7A10 in the brain, e.g., serine, glycine and cysteine, 
have central roles in one-carbon metabolism, the methionine cycle, glutathione synthesis and redox 
balance (6,7,10,11), the AAs carried by SLC7A10 in adipocytes and the consequent metabolic 
effects are unknown. By transcriptome screens and interrogation of several human obesity cohorts 
along with functional experiments, we here uncover SLC7A10 as an important novel regulator of 
core metabolic functions in white adipocytes, providing new insight into the development of 
obesity and insulin resistance.  
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RESEARCH DESIGN AND METHODS 
Human cohorts and samples 
Anthropometric data are summarized in Table 1 (7 cohorts).  
 
RNA and gene expression analyses 
Whole AT was homogenized or fractionated into isolated adipocytes or stromal vascular fraction 
(SVF), and RNA was purified, as described previously (12). Global gene expression in whole AT 
was measured by microarrays as described previously for the BPD-Fat cohort (13), Sib Pair cohort 
(14), VLCD study (baseline data) (15) and RIKEN cohort (16). qPCR was performed with SYBR 
Green dye following cDNA synthesis using high-capacity cDNA reverse transcription kit (Applied 
Biosystems) (Supplementary Table 1).   
 
Human cell cultures 
Primary human adipocyte cultures  
Human liposuction aspirates from the abdomen and flanks were collected with informed consent 
from donors undergoing cosmetic surgery at Aleris medical center and Plastikkirurg1 in Bergen, 
Norway. The donors comprised 18 women and 1 man between 21 and 68 years of age (46.3±12.4) 
and with BMI between 24.3 and 32.8 (27.9±2.7), all free of diabetes and otherwise healthy 
(Supplementary Table 2).  
 
Isolation and culturing of human stromal vascular fraction  
The stromal vascular fraction (SVF) from SC AT was isolated as previously described (17) with 
some modifications. Briefly, KRP-buffer containing Liberase Blendzyme 3 (Roche) and DNase 
was added to the liposuction aspirate. Following a 1-hour incubation at 37°C, the digested fat tissue 
was filtered,washed with 0.9% NaCl and centrifugated.. Red blood cells were lysed (NH4Cl (155 
mM), K2HPO4 (5.7 mM) and EDTA (0.1 mM)). Preadipocytes were seeded and cultured in 
GlutaMAX DMEM (Thermo Fisher) supplemented with 10% fetal bovine serum (FBS) and 50 
μg/ml gentamicin (Sigma) and grown at 37°C with 5% CO2. The following day, differentiation of 
primary human adipose cells (human adipose stromal cells, hASCs) was induced by supplementing 
the culture medium with 33 μM biotin, 1 nM triiodothyronine, 17 μM DL-pantothenate, 10 μg/ml 
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transferrin, 66 nM insulin, 100 nM cortisol, 15 mM Hepes and 10 μM rosiglitazone. Rosiglitazone 
was discontinued after 6 days and terminal differentiation was defined at 12-13 days. 
 
Mouse cell cultures and primary cells 
3T3-L1 mouse preadipocytes were cultured and differentiated as described previously (18).  
 
SLC7A10 inhibitors 
BMS-466442 (AOBIOUS), referred to as SLC7A10 inhibitor 1 (19), and Lu AE00527, referred to 
as SLC7A10 inhibitor 2 (20), were used to inhibit SLC7A10 function in in vitro cell culture 
experiments at a standard final concentration of 10 µM. The latter inhibitor was provided by H. 
Lundbeck A/S (Valby, Denmark). 
 
Gene expression analysis  
Total RNA from human and mouse cell cultures was isolated using RNeasy kit (QIAGEN) and 
quality checked by QIAxpert spectrophotometer (QIAGEN) prior to cDNA synthesis with 200 ng 
RNA input using a high-capacity cDNA reverse transcription kit (Applied Biosystems). cDNA 
was analyzed by Lightcycler480 (Roche) quantitative real-time PCR using SYBR Green dye 
(Roche) and target primers (Supplementary Table 1). Relative mRNA expression was 
determined by standard curves and normalized to reference gene (HPRT or Rps13). Prior to RNA 
sequencing, samples were DNase treated and RNA integrity number (RIN>9) was confirmed by 
Bioanalyzer (Agilent). cDNA libraries were generated using TruSeq Stranded mRNA Library Prep 
kit and sequenced by Illumina Hiseq 4000. Reads were mapped against the Human genome 
(GrCH38) using HiSat (Version 2.1.0), tabulated by featureCounts (Version 1.5.2) and analyzed 
using DESeq2 (Version 1.22.2).  
 
Co-expression, gene ontology (GO) and pathway analysis 
Co-expression analysis was performed based on global gene expression data for human adipocytes 
isolated directly from biopsies of 12 lean and 12 obese patients (ADIPO cohort). Pearson 
correlation coefficients were calculated for correlations between SLC7A10 mRNA and all other 
transcripts globally (around 47,000 probes, including 21,000 individual genes) across the 24 
patients. Genes with correlation coefficients (β) β>0.65 or β<-0.65 were analyzed using 
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PANTHER Gene List Analysis tool (http://www.pantherdb.org/) to perform statistical 
overrepresentation test (binomial statistics, Bonferroni-corrected for multiple testing). RNA-seq 
results from hASCs were analyzed by PANTHER (v.14.0), utilizing Fisher’s exact test (21).  
 
Transfection: 
Transfection with mouse Slc7a10 expression plasmid was performed using the transfection reagent 
TransIT-L1, following the manufacturer’s protocol (Mirus Bio LCC). 2.0 µg of Slc7a10 plasmid 
or empty vector was used per ml medium (Supplementary Table 3).   
 
Western blotting 
Cells were lysed in RIPA buffer (Thermo Fisher) containing EDTA-free protease inhibitor cocktail 
(Roche) and PhosphoStop (Sigma). Protein content in the lysates was determined using DC protein 
assay (Bio-Rad), loaded onto 4-20% TGX gels (Bio-Rad) and subjected to SDS-PAGE prior to 
transfer to nitrocellulose membrane. Membranes were developed using Femto solution (Thermo 
Scientific) and target protein amount relative to endogenous control was quantified by 
densitometry. 
 
Amino acid quantification  
Extracellular (medium) AA concentrations were assayed by GC-MS/MS (Agilent) (22). Flux was 
calculated based on AA concentration in unconditioned and conditioned medium. 
 
Radiolabeled amino acid uptake assays 
AA uptake was measured in sodium-free assay buffer, as described previously (19), using 
unlabeled controls (D- or L-Serine, final concentration 10 mM) and stock solutions of D-[3H] 
Serine (15 Ci/mmol) and L-[14C] Serine (100mCi/mmol) (Perkin Elmer). Sample radioactivity was 
measured as 5-minute averaged CPM (QuantaSmart software).  
 
Mitochondrial respiration assay 
Cellular respiration was measured by the Seahorse Mito Stress Test kit and XF96 analyzer 
(Agilent). Preadipocytes were seeded in gelatin-coated (0.1% w/v)  microplates and differentiated. 
Cells were washed and treated in XF base medium supplemented with L-glutamine (2 mM), 
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sodium pyruvate (2 mM) and glucose (10 mM) and incubated in a CO2-free incubator for 1 hour. 




Lipid accumulation was assessed by Oil red O (ORO) staining as described previously (23).  
 
Radiolabeled glucose uptake assays 
Adipocytes were washed with PBS and incubated overnight in glucose reduced DMEM w/wo 
treatment. Subsequently, cells were starved in glucose-free medium w/wo treatment for 2.5 hours. 
Insulin (final concentration 10nM) was added to indicated wells for 30 minutes prior to the assay. 
Deoxy-D-[14C]-Glucose (57.7mCi/mmol) (Perkin Elmer) was added for 30 minutes and incubated 
at 37 ⁰C. Cells were placed on ice,washed and lysates were collected in Ultima Gold fluid 
cartridges (Perkin Elmer). Isotope retention in lysate was measured as 5-minute averaged counts 
per minute (CPM) (QuantaSmart software) in a scintillation counter.  
 
Reactive Oxygen Species (ROS) assay 
Adipocytes were incubated for 30 minutes with or without 5μM CM-H2DCFDA as described 
previously (24). Cells were washed and incubated in Krebs-ringer bicarbonate (KRB) buffer or 
sodium-free assay buffer, with indicated compounds, followed by measurement of fluorescent 
emission of oxidized H2DCFDA probe (538nm following 485nm excitation) using a SpectraMax 
Gemini EM (Molecular Devices) plate reader at 37 °C. 
 
Glutathione assay 
Total glutathione was measured using the GSH/GSSG-GloTM Assay (Promega), according to the 
manufacturer’s protocol. Briefly, cells were lysed with glutathione lysis reagent and incubated in 
luciferin generation reagent for 30 minutes at RT. Samples were incubated for 15 minutes 
following addition of luciferin detection reagent. Luminescence was measured using FLUOstar 
OPTIMA EM (Thermo Fisher Scientific).  
 
In vivo Zebrafish model 
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Heterozygous slc7a10b loss-of-function Danio rerio (zebrafish) were obtained from The Zebrafish 
Model Organism Database (ZFIN, genomic feature sa15382) and crossed to obtain homozygote 
and wild-type (WT) zebrafish.  
 
Genotyping 
Genomic DNA was extracted from caudal fin biopsies of mature Zebrafish using DNeasy kit 
(QIAGEN). For genotyping, a 298 bp region of the slc7a10b gene containing the intron splice site 
A→T mutation was amplified by PCR using Platinum Taq High Fidelity DNA Polymerase 
(Invitrogen) and the flanking primers 5’-TCGCCTACTTCTCCTCCATG-3’ (forward) and 5’-
TTCCCAAGTCCTCCTGATGC-3’ (reverse). Samples were subjected to endonuclease digestion 
using the restriction enzyme AccI (New England Biolabs) prior to band separation by agarose gel 
electrophoresis. Genotypes were determined based on signature fragment digestion of the PCR 
product where the A→T mutation abolished the AccI recognition cleavage site. 
 
Selection and genomic features 
The ZFIN genomic feature sa15382 zebrafish used in this study exhibited a p 
oint mutation in the conserved 3’ splice site between exon 6 and 7 in the slc7a10b gene 
(ENSDART00000073398.5). This A→T mutation disrupts the dinucleotide splice site, and the 
intron between exon 6 and 7 is not spliced during maturation of the mRNA. Thus, the mRNA 
length is increased and the slc7a10b protein product is inactive. Heterozygous larvae were raised 
and bred to obtain zebrafish homozygous for this mutation. Due to the large variation in body 
weight between male and female zebrafish in a pilot study, the overfeeding study was performed 
using male zebrafish. 
  
Husbandry 
4-month-old male zebrafish were housed in 3-liter tanks (on average 20 per tank) with a 
recirculating system (Aquatic Habitats, Pentair AES) at 28.5±1 °C and pH 7.5±0.3, with 10% daily 
water exchange, electrical conductivity of 500 ±50μs, and a 14h light and 10h dark circadian cycle. 
Zebrafish were fed 8.2 mg Gemma Micro 500 (Skretting, USA) per day, divided over three 
timepoints (at 8am, noon and 4pm), in addition to freshly hatched Artemia (3 drops of a 24h 
Artemia culture) once per day. Gemma Micro 500, which the zebrafish were fed both under normal 
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and overfeeding conditions, consisted of fishmeal, lecithin, wheat gluten, zebrafish oil, vitamins 
and mineral premixes and betaine, containing 59% (w/w) protein sources and 14% (w/w) lipids 
(containing 14% omega-3 fatty acids).  
 
Overfeeding  
Three adult zebrafish were held per 1.5-liter tank, in total 33 WT and 39 loss-of-function zebrafish. 
To promote weight gain, 12.3 mg feed per zebrafish per day (50% more feed than normal) was 
given for the first 3 weeks and 16.4 mg (100% more feed than normal) for the last 5 weeks of the 
overfeeding study. The circulation system was turned off for 5 minutes before and 30 minutes after 
each feeding, allowing consumption of all supplied food. Zebrafish were otherwise fed as under 
normal conditions (described above). 
 
Measuring and weighing 
Zebrafish length and weight was recorded at the start and the end of the study, while weight was 
also measured after 3 and 6 weeks. Since it was not feasible to control the feed intake of each 
individual fish, recorded data, and tissue samples from the three zebrafish in each tank were 
combined to obtain an average for each tank. Before all handelling, each zebrafish was sedated 
using 75 mg/L to 200 mg/L Tricain mesylate (Pharmaq).  
 
Sample collection and RNA sequencing 
Following sacrifice, tissue biopsies from three zebrafish in each tank were pooled together and 
snap-frozen in liquid nitrogen. Adipose and liver biopsies were fixed in 4% (v/v) 
paraformaldehyde in 0.1 M phosphate buffer for 12 hours and paraffin embedded after gradual 
dehydration as described previously (25). Slice sections of 5µm were stained with hematoxylin 
and eosin, and adipocyte size was analyzed and quantified using Image J open-source software as 
described elsewhere (18). Total RNA from zebrafish visceral adipose tissue (VAT) was prepared 
for RNA-seq as described for human adipose cultures, as well the generation of cDNA libraries. 
Sample reads were mapped against the Zebrafish genome (GRCz10) using HiSat (Version 2.05), 






Differences between groups in human cohort data were analyzed using paired t-test, one or two-
way ANOVA, and are presented as mean ± SD. For Pearson correlation and multiple regression 
analyses, adjustments for BMI and sex are indicated. Differences between groups in cell culture 
experiments were assessed using two-tailed unpaired student’s t-test or one-way ANOVA with 
Dunnett’s or Sidak’s correction for multiple comparisons. Sample data from empirical experiments 
were assumed to be normally distributed and results are presented as mean ± SD, except for the 
Seahorse data which are presented as geometric mean ± 95% confidence interval. All data were 
subjected to a Box Whiskers Tukey test to detect and remove outliers. Statistical significance was 
calculated in GraphPad or with the R bio conductor package limma v3.34.9. Statistical details and 
the number of biological samples (n) for all experiments are provided in the figure legends. For 
cell experiments, n annotates the number of parallel wells per treatment. For zebrafish samples, n 
annotates the number of zebrafish per treatment. For qPCR data, n annotates either the number of 
patients, or the number of wells in a cell experiment.   
 
Study approval 
All human samples analyzed in the present study were obtained with written informed consent and 
approval given by the respective regional ethics committees (2010/502 and 2010/3405, REC West 
Norway; Dnr 721-96 and S 172-02, REC in Gothenburg, Sweden; 2009/1881-31/1, 2011/1002-
31/1 and 2015/530-32, Committee of Ethics at Karolinska Institutet, Stockholm, Sweden; and the 
Ethics Committee of the University of Leipzig, Germany).  
 
Zebrafish were raised and cared for according to the Norwegian Animal Welfare Act guidelines, 
and all experiments after 5 days post fertilization (dpf) were approved by the Norwegian Food 
Safety Authority (FOTS ID 9199).  
 
Data and resource availability  
Datasets generated and/or analyzed during the current study are available from the corresponding 
author upon reasonable request. In addition, the RNA sequencing datasets in this publication have 
been deposited in the NCBI’s Gene Expression Omnibus (26) and are accessible through GEO 




Implication of adipocyte SLC7A10 in abdominal adiposity and insulin resistance  
In transcriptome screens of adipose samples from people at the peak of extreme obesity (BPD-Fat 
cohort, Table 1), we prioritized candidate genes with concomitant differential expression in two 
separate disease-relevant comparisons of adipose function: visceral (omental, OM) and abdominal 
SC AT in extreme obesity, and before and after profound fat loss (SC AT from the same patients). 
This combined transcriptome screen identified 65 genes with both depot- and fat loss-dependent 
expression (fold change ≥ 1.5 and q-value < 0.01 cutoffs in both analyses) (Supplementary Table 
4). Further supporting a role for many of these genes in insulin resistance, we found strong 
significant correlations for 27 of the 65 genes (42%) with waist-to-hip ratio (WHR) adjusted for 
BMI and sex, in a second cohort of 88 people (Sib Pair cohort) (Supplementary Table 4) (14). 
Among these genes, only 5 (8%) showed inverse correlations with WHR, 4 of which displayed 
highest expression in OM AT and up-regulation in SC AT after profound fat loss (CIDEA, 
SLC7A10, GPD1L and HOXA5) (Supplementary Table 4). Among the 27 candidates, we 
additionally prioritized genes with high expression in adipocytes specifically, based on a cohort 
containing isolated adipocytes and stromal vascular fraction (SVF) (ADIPO cohort). Calculation 
of adipocyte/SVF expression ratios revealed CIDEA and SLC7A10 as stand-out candidates with 
similar expression profiles (Figure 1A). While previous studies have investigated functional roles 
of CIDEA in adipocytes (27), there is a paucity of functional data on adipocyte SLC7A10.  
 
qPCR analysis of a larger cohort of people with severe obesity (WNOB cohort) confirmed the 
adipose depot- and fat-loss dependent expression pattern of SLC7A10 (Figure 1B). SLC7A10 
mRNA was also higher in OM compared to SC samples in both isolated adipocytes and SVF 
(ADIPO cohort), but with diminished expression in SVF (Figure 1C). Consistent with increased 
SC SLC7A10 expression after surgery-induced fat loss (Figure 1C), SC adipocytes and SVF from 
lean people showed higher expression than samples from those with obesity (Figure 1C). 
Furthermore, insulin resistant obese (IRO) patients showed lower SLC7A10 mRNA compared to 
BMI-matched insulin sensitive obese (ISO) patients (28), in SC as well as OM fat (ISO cohort) 
(Figure 1D). Consistently, SC whole tissue SLC7A10 mRNA levels showed strong inverse 
correlations with HOMA-IR, triacylglycerol (TAG) levels, SC adipocyte volume, WHR and 
visceral fat volume (Figure 1E, Supplementary Figure 1). On the other hand, SC SLC7A10 
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mRNA showed positive correlations with SC adipocyte number and SC abdominal fat mass when 
adjusting for BMI and sex (Figure 1E, Supplementary Figure 1). Finally, comparing patients 
with and without type 2 diabetes in the WNOB morbid obesity cohort, we observed decreased 
SLC7A10 mRNA expression in omental as well as SC post-surgery AT (Figure 1F). 
 
Loss of Slc7a10b function in zebrafish causes body weight gain and visceral adipocyte 
hypertrophy 
To determine a potential causal role for SLC7A10 in the regulation of fat storage and adipose 
metabolism, we obtained zebrafish containing a splice site (loss-of-function) mutation in intron 6 
of Slc7a10 isoform b. After 2 months of overfeeding, the knockout zebrafish had on average 
gained 38% more body weight than their wildtype (WT) counterparts (Figure 2A). Assessing AT 
morphology, we observed on average 49% larger adipocytes in the loss-of-function zebrafish 
compared to WT (Figure 2B,C). Histological analyses of liver, which may reveal altered 
morphology related to impaired fatty acid oxidation (i.e., fatty liver), showed no apparent 
differences in cell size and lipid droplet formation between the Slc7a10b loss-of-function and WT 
zebrafish (Figure 2C).  
 
SLC7A10 is upregulated in mature adipocytes and regulates lipid metabolism  
We consequently explored mechanisms of the fat accretion by studying direct effects of altered 
SLC7A10 function in adipocytes. In differentiated mouse 3T3-L1 adipocytes and primary human 
adipose stromal cells (hASCs), SLC7A10 showed a marked increased mRNA and protein 
expression  (Figure 3A-D. To study the consequence of decreased SLC7A10 function in 
adipocytes, we inhibited SLC7A10 using the selective inhibitors BMS-466442 (SLC7A10 
inhibitor 1) (19,29) or Lu-AE00527 (SLC7A10 inhibitor 2) (20) during differentiation and 
observed increased lipid accumulation in 3T3-L1s (Figure 3E) as well as hASCs (Figure 3F) 
compared to controls. 
 
Adipose SLC7A10 impairment affects energy metabolic pathways 
To systematically explore SLC7A10-dependent metabolic processes, we first correlated mRNA 
levels of SLC7A10 and other genes in a global transcriptome analysis of adipocytes isolated 
directly from human SC fat biopsies (ADIPO cohort). Subjecting the most SLC7A10-correlated 
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transcripts to gene ontology analysis, we found that genes anti-expressed to SLC7A10 (113 unique 
genes, Supplementary Table 5) mapped primarily to cellular/developmental processes and 
protein transport (Figure 4A), and co-expressed genes (323 unique genes, Supplementary Table 
5) to lipid metabolic processes and oxidative phosphorylation (Figure 4A). Moreover, RNA-seq 
in SLC7A10 inhibitor-treated primary human adipocytes revealed a profound transcriptome effect 
(Supplementary Figure 2A-C). Among 862 significantly downregulated genes , gene ontology 
analysis revealed an enrichment of genes involved in biological processes such as immune 
response, inflammation, extracellular matrix organization and cell differentiation (Supplementary 
Figure 2D). Among 1,113 significantly upregulated genes there were striking enrichments for 
isopentenyl diphosphate biosynthetic process (26-fold), NADPH regeneration (26-fold), pentose 
phosphate shunt (26-fold), triglyceride biosynthetic process (9.3-fold) and glutathione metabolic 
processes (8.2-fold) (Supplementary Figure 2D), indicating mechanisms that fueled lipid 
storage. Additionally, by pathway analysis we found a marked enrichment of genes involved in 
ATP synthesis (16-fold), TCA cycle (13-fold) and cholesterol biosynthesis (12-fold) among 
upregulated genes, and in, e.g., glycolysis and angiogenesis for the downregulated genes (Figure 
4B,C). 
 
Global gene expression in VAT from Slc7a10b loss-of-function and WT zebrafish was also 
assayed by RNA-seq. Visualization of RNA-seq reads identified the expected mutation in the 
splice site of exon 6 (Supplementary Figure 3A). Of note, mutants exhibited increased mRNA 
levels of the defective Slc7a10b (Supplementary Figure 3B), compensatory to the impaired 
splicing and function. Before further analysis, we removed outliers using multidimensional scaling 
plots (Supplementary Figure 3C) and excluded samples that differed significantly from the 
others in the expression of immediate-early stress-responsive genes (Supplementary Figure 3D). 
RNA-seq revealed 1,736 differentially expressed genes in the Slc7a10b loss-of-function zebrafish, 
including 880 upregulated and 856 downregulated transcripts. The loss-of-function caused a 
particularly striking upregulation of Urahb which encodes an enzyme that regulates degradation 
of uric acid to (S)-allantoin (Supplementary Figure 4A,B), a product of purine nucleotide 
degradation and a marker of oxidative stress in most non-human mammals. Consistently, both 
urate, purine nucleobase- and hydrogen peroxide metabolism were among the most affected 
biological processes in the zebrafish VAT, together with, e.g., oxygen transport, AA metabolism, 
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lipoprotein remodeling, and lipid- and citrate transport (Supplementary Figure 4B). The RNA-
seq analysis for SLC7A10 inhibition in the differentiating hASCs largely supported an effect on 
these processes, including steroid biosynthesis and oxidation-reduction process (Supplementary 
Figure 5A). 121 of the 216 gene ontology terms identified in the zebrafish dataset overlapped with 
the human dataset. While genes in some terms showed opposite directionality of expression, 
several of the most significant terms in zebrafish showed the same directionality in human cells 
(Supplementary Figure 5A). . From the 444 differentially expressed genes in the zebrafish 
dataset, 26 genes overlaped with the human dataset, of which 17 were regulated in the same 
direction. Among these were SLC7A10 (reflecting a compensatory up-regulation), SCD (a marker 
of nutritionally regulated lipid storage), HSD17B10 (an isoleucine catabolizing enzyme), PKM and 
PC (related to pyruvate metabolism and glyceroneogenesis which provides glycerol for lipid 
storage), and CPT1A (rate-limiting for mitochondrial lipid β-oxidation) (Supplementary Figure 
5B). 
 
In accordance with the transcriptome changes indicating effects on mitochondrial function, 
SLC7A10 inhibition for 24 hours decreased basal respiration, ATP synthesis, maximal 
consumption rate and spare respiratory capacity by up to 50% in murine (Supplementary Figure 
6A,B) and primary human adipocytes (Figure 5A), with detectable effects after 2-hour inhibition. 
Exposure to SLC7A10 inhibitor 2 (Lu) reproduced the suppression of maximal consumption rate 
and spare respiratory capacity (Figure 5B). Conversely, overexpressing Slc7a10 (Supplementary 
Figure 6C) in murine fat cells increased these measures along with basal respiration and ATP 
synthesis (Figure 5C). 
 
SLC7A10 transports serine in adipocytes  
To examine the mechanism by which SLC7A10 modulates adipocyte metabolism, we tested the 
effect of SLC7A10 inhibition on the flux of neutral AAs, some of which are direct precursors of 
glutathione (e.g., cysteine, glycine and serine) (6,7). SLC7A10 impairment strongly increased 
medium concentrations of serine from around day 8 of human adipocyte differentiation, while 
concentrations of other SLC7A10-linked neutral AAs showed only minor effects (Figure 6A, 
Supplementary Figure 7A). We confirmed the reduction in serine influx in response to SLC7A10 
inhibition in cultured adipocytes from four independent donors (Supplementary Figure 7B). 
13 
 
Additionally, using radiolabeled AAs in sodium-free conditions, SLC7A10-inhibition  reduced 
uptake of D-serine (Figure 6B and S7C) and L-serine in adipocytes  (Supplementary Figure 
7C,D). The primary effect on serine transport is consistent with an important role for this AA in 
lipid synthesis, antioxidant regeneration, TCA cycle, glycolysis and oxidative phosphorylation, in 
part because serine serves as a key methyl donor that controls biosynthesis and regeneration of 
ATP, NADPH, purines, glutathione and other molecules through one-carbon metabolism (11) 
(Figure 6C). 
 
SLC7A10 modulates glutathione levels, ROS generation and insulin-stimulated glucose 
uptake in adipocytes 
The effects of SLC7A10 inhibition on several genes in NADPH- and glutathione-related 
metabolism (Figure 6D) prompted us to examine if SLC7A10 affects cellular glutathione levels. 
SLC7A10 impairment decreased total glutathione levels detected after only 15-45 minutes 
inhibition in murine and human adipocytes (Figure 6E,F). The decrease was confirmed with 
inhibitor 2, albeit not significant in the human adipocytes (Figure 6E,F), while SLC7A10 
overexpression in 3T3-L1 adipocytes increased total glutathione levels (Figure 6G). Consistently, 
intracellular ROS levels increased progressively after 20 minutes of SLC7A10 inhibition in 3T3-
L1 adipocytes (Figure 6H) and after 60 minutes in mature human adipocytes (Figure 6I), while 
SLC7A10 overexpression reduced ROS generation (Figure 6J). Interestingly, when treating 
SLC7A10-inhibited adipocytes with the ROS scavenger N-acetyl-L-cysteine (Nac), we observed 
a 50% to 70% reduction in lipid accumulation (Figure 6K), indicating that ROS generation may 
have partially mediated the lipid-storing effect of reduced SLC7A10 activity. On the other hand, 
this partial reversal of SLC7A10 inhibitor-dependent lipid accumulation by Nac was not clear 
upon prolonged stimulation with insulin, which increased lipid accumulation to a similar degree 
as SLC7A10 inhibition (Figure 6K). These data suggest that the lipid storing effects of SLC7A10 
impairment might at least partially involve increased levels of ROS, whereas the effects of insulin 
may largely occur independent of ROS generation. 
 
Finally, we tested if reduced SLC7A10 activity also affects insulin-stimulated glucose uptake. 
Inhibition of SLC7A10 diminished insulin-stimulated glucose uptake in mouse and human 
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We here identified SLC7A10 as a novel facilitator of serine uptake in adipocytes, and that this 
function may buffer against oxidative stress, lipid accumulation, insulin resistance and 
dyslipidemia. Our data show that pharmacological inhibition of SLC7A10 in adipocytes decreases 
glutathione levels (within minutes), increases ROS generation (within an hour), decreases 
mitochondrial respiratory capacity (within hours) and promotes lipid accumulation (within days). 
SLC7A10 inhibition also decreases insulin-stimulated glucose uptake. Furthermore, SLC7A10 
overexpression showed inverse effects, suggesting that SLC7A10 activation may improve 
important metabolic functions in adipocytes, potentially counteracting development of obesity and 
insulin resistance. The overfeeding experiments in zebrafish support that functional impairment of 
SLC7A10 increases body weight and adipocyte size in vivo.  
 
Our clinical cohort data reveal consistent inverse correlations between adipose SLC7A10 mRNA 
expression and several key features of insulin resistance, including WHR, adipocyte hypertrophy, 
visceral fat mass, TAG and HOMA-IR after adjustment for BMI and sex, further underscored by 
increased SLC7A10 mRNA in people with insulin sensitive compared to insulin resistant obesity. 
SC adipose SLC7A10 was previously shown to have a strong heritable expression (h2 = 0.79), to 
be lower in people carrying type 2 diabetes risk variants in the KLF14 locus, and to correlate 
negatively with metabolic traits linked to disease risk (30).  
 
The potential clinical relevance of SLC7A10 in adipocyte metabolism is further supported by 
previously unconnected lines of evidence from other studies. Firstly, a metabolomics study found 
reduced uptake of serine in VAT from people with severe obesity compared to non-obese 
participants (31) . Secondly, total glutathione levels are higher in OM than SC AT of lean 
individuals, and altered glutathione synthesis in adipocytes affects insulin sensitivity (32,33). 
Moreover, total glutathione levels are reduced in AT of people with obesity compared to lean 
people (34), in line with the pattern of SLC7A10 expression reported here. Thirdly, SC AT in 
obesity and type 2 diabetes exhibits increased mitochondrial ROS levels, e.g., hydrogen peroxide 
(H2O2), combined with reduced expression of antioxidant enzymes (35). A recent report showed 
46% higher H2O2 levels in visceral fat of men with central obesity compared to lean men, and 
positive correlations of the adipose H2O2 concentrations with insulin resistance (36). Importantly, 
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recent studies suggest that oxidative stress in adipocytes is not only a consequence of metabolic 
disease, but also a cause (37), and that elevated intracellular ROS levels in adipocytes might 
contribute to adipocyte dysfunction, increased fat storage and insulin resistance (24,38). Taken 
together, our study points to SLC7A10 as a potential candidate for therapeutic intervention to 
mitigate oxidative stress and unhealthy lipid storage in adipocytes. 
 
In line with our experimental data linking reduced SLC7A10 function to increased lipid 
accumulation via decreased glutathione levels and elevated ROS, glutathione depletion has been 
found to promote adipogenesis in 3T3-L1 adipocytes (39). Although a recent study in 3T3-L1 
adipocytes found that long-term treatment with the ROS scavenger Nac increased ROS levels (40), 
others found that Nac treatment decreased ROS levels (as expected), while increasing oxygen 
consumption,decreasing body fat in mice in vivo (41) and inhibiting insulin-stimulated lipid 
accumulation in 3T3-L1 adipocytes (42), in line with our data. ROS can modulate intracellular 
signaling and a transient increase in ROS levels can promote adipocyte differentiation (38,43), 
while sustained elevation of cellular ROS levels has been linked to adipocyte lipid storage (24), 
also observed in microorganisms (44). Our data shows a clear positive relationship between ROS 
levels and lipid accumulation in contrast to a recent study in mice, where increased mitochondrial 
levels of the H2O2 hydrolyzing enzyme catalase were associated with reduced ROS, increased 
adiposity,adipocyte size and adipose glyceroneogenic and lipogenic gene expression (45). Another 
study also found reduced body weight with increased ROS levels in AT with aging (46). A possible 
explanation for these inconsistent  results might be the specific metabolic contexts and distinct 
effects of specific sources of ROS on glyceroneogenesis and lipid accumulation, which requires 
further investigation. 
 
It is possible that inhibition of SLC7A10 and the concomitant increase in ROS levels promoted 
lipid storage in our study, at least in part, by reducing mitochondrial respiratory capacity. A recent 
study in SC and visceral human adipose-derived stem cells linked high ROS generation to 
decreased mitochondrial respiration (47), and increased ROS generation in epididymal fat has been 
shown to precede lowered mitochondrial biogenesis in nutritionally challenged mice (48). 
Additionally, elevated mitochondrial and extracellular ROS concentrations have been shown to 
inhibit mitochondrial respiration and to cause mitochondrial dysfunction in cultured 3T3-L1 and 
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primary rat adipocytes (24,41). Recent studies also showed that ROS can impair insulin-dependent 
glucose uptake (4,49) in line with the SLC7A10-dependent phenotype we observed .  
 
While our data indicate that altered serine uptake mediated the lipid-storing effects of impaired 
SLC7A10 function, effects of serine on adipocyte metabolism and mechanisms regulating 
adipocyte serine flux are largely unknown. Serine is vital in maintaining mitochondrial respiration 
(50,51) and both imported and de novo synthesized serine play a role in protein, lipid and purine 
metabolism (11). In mouse embryonic fibroblasts lacking the first enzyme in de novo serine 
synthesis, external L-serine depletion increased formation of specific sphingolipids (52)  and serine 
supplementation in mice reduced hepatic ROS levels ameliorating alcoholic fatty liver by 
supporting glutathione levels (53,54). 
 
Our study has limitations. The SLC7A10 inhibitors BMS-466442 and LU AE00527 have been 
used to study functions of SLC7A10 in the brain, and show high selectivity (19,20,29,55). 
However, we cannot entirely rule out nonspecific effects, even though overexpression of 
SLC7A10 showed inverse effects compared to loss of SLC7A10 function in adipocyte cultures. 
Previous studies have shown the utility of zebrafish for investigating AT biology and the dynamics 
of obesity and type 2 diabetes development (56,57), and they share common obesity-related 
pathophysiological pathways with mammals (58). Nonetheless, future studies should perform 
adipocyte selective Slc7a10 manipulation, e.g., by overexpression in mice to determine to what 
degree maintained Slc7a10 activity can prevent and reverse obesity and systemic insulin 
resistance. Additionally, further studies are needed to determine whether loss of SLC7A10 activity 
directly in visceral fat, where SLC7A10 mRNA is 2-fold higher than in SC fat, might render this 
depot particularly vulnerable to adipocyte hypertrophy and metabolic dysfunction. 
 
In conclusion, our study has identified SLC7A10 as a novel gene involved in the regulation of 
adipocyte energy metabolism, ROS generation and lipid accumulation, implicating novel 
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Table 1. Overview of the analyzed human cohorts. 
 
 
aSLC7A10 expression was measured in isolated adipocytes and stromal vascular fraction (SVF) 
bSLC7A10 expression was measured in isolated adipocytes 
Abbreviations: BMI, body-mass index; WHR, waist-hip ratio; T2D, type 2 diabetes; 1y post-op, one year after 







Age BMI  
(kg/m2) 
WHR  % T2D Tissue Expression Figure/ 
Dataset 
BPD-Fat          
Obese 12 25 40.4 ± 12.5 
51.5 ± 4.9 n/a 42 SC/OM 
Illumina Supplementary 
Table 4 
Post 1 year 12 25 42.2 ± 11.7 32.9 ± 5.6 n/a 0 SC   
SibPair          
Non-Obese/obese 88 47 65.9 ± 6.7 29.3 ± 5.5 0.94 ± 0.08 18 SC Affymetrix Supplementary 
Table 4, 1E 
VLCD          
Obese 24 75 48.3 ± 10.4 37.6 ± 4.9 1.02 ± 0.08 29 SC Affymetrix 1E, S1B 
ADIPO          
Obese  12 33 43.1 ± 10.4 43.8 ± 5.4 n/a 17 SC/OM a Illumina 1A, 1C,  
Lean 12 42 43.5 ± 12.1 22.8 ± 2.2 





WNOB          
Obese 324 21 40.4 ± 12.5 42.4 ± 5.4 n/a 21 SC/OM qPCR 1B 
Post 1 year 137  42.6 ± 11.8 28.9 ± 5.2 n/a 0 SC qPCR  
Non-obese 59 82 49.1 ± 16.5 24.7 ± 3.1 n/a 0 SC qPCR  
ISO          
Obese IR 40 50 51.5 ± 9.7 45.5 ± 1.4 n/a 0 SC/OM qPCR 1D 
Obese IS 40 50 51.4 ± 9.6 45.1 ± 1.8 n/a 0 SC/OM qPCR  
RIKEN          





Figure 1. SLC7A10 mRNA expression is high in visceral adipose tissue, and correlates inversely with obesity 
and insulin resistance. SLC7A10 mRNA expression was measured in human visceral (omental, OM) and 
subcutaneous (SC) adipose samples by microarrays or by qPCR (calculated relative to HPRT mRNA). 
(A) Adipocytes and stromal-vascular fraction (SVF) were isolated from OM and SC adipose tissues of people with 
severe obesity (n=12) (ADIPO cohort). SLC7A10 mRNA expression was measured by Illumina microarrays and genes 
enriched in the adipocyte fraction relative to SVF are shown. Data are presented as median ± IQR. 
(B) SLC7A10 mRNA was measured by qPCR in OM and SC adipose tissues collected from people with morbid obesity 
(BMI ≥ 40 kg/m2, or above 35 kg/m2 with at least one obesity-related health condition) and SC adipose tissue collected 
one year after profound fat loss following bariatric surgery from the same subjects (Post-WL) (n =101 pairs) Data are 
presented as mean ± SD. 
(C) Adipocytes and SVF were isolated from OM and SC adipose tissues of lean people (n=12) and people with severe 
adiposity (n=12) (ADIPO cohort). SLC7A10 mRNA expression was measured by Illumina microarrays. Data are 
presented as mean ± SD. 
(D) SLC7A10 mRNA was measured by qPCR in OM and SC adipose tissues in a cohort of 40 insulin-sensitive obese 
(ISO) and 40 insulin-resistant obese IRO people (ISO cohort), where insulin resistance was measured by 
hyperinsulinemic-euglycemic clamp. Data are presented as mean ± SD. 
(E) Correlations of SC adipose tissue SLC7A10 mRNA with clinical parameters in the RIKEN (n=56), VLCD (n=24) 
and Sib Pair (n=88) cohorts, calculated as Spearman’s rho with and without adjustment. Data are adjusted for BMI 
and sex for Sib Pair and VLCD cohorts and for BMI for RIKEN cohort. Symbols outlined in bold indicate statistical 
significance. 
(F) SLC7A10 mRNA was measured in OM (n= 88), SC (n=81) and post-WL SC (n= 88) adipose tissues of obese 
people without diabetes, and in OM (n= 22), SC (n =23) and post-WL SC (n=24) adipose tissues of obese people with 
diabetes in the WNOB cohort. Data are presented as mean ± SD. OM, omental; SC; subcutaneous; Post-WL- post-
weight loss. 
 *, p<0.05. **, p<0.01. ***, p<0.001. 
 
Figure 2. Loss of SLC7A10 function in zebrafish in vivo causes body weight gain and visceral adipocyte 
hypertrophy. Four-month-old wildtype (WT) and Slc7a10b loss-of-function mutant male zebrafish were fed 50-
100% more than their regular feed for 8 weeks. Body weight and length were recorded at start and end, and weight, 
length and adipose morphology were assessed after sacrifice. Visceral adipose tissue from three zebrafish housed in 
same tank during overfeeding was pooled and RNA was isolated. 
(A) Body weight and length were measured before and after overfeeding of the zebrafish. Data are presented as mean 
± SD (WT (n=31) and loss-of-function (n=36)). 
(B-C) Visceral adipose and liver tissue were fixed, sectioned (5µm) and stained with hematoxylin and eosin for 
morphological analyses. Adipocyte size was analyzed and quantified using Image J and average adipocyte size was 
calculated for each section (WT (n=27) and loss-of-function mutant (n=29)). Pictures representative of the group 
averages are shown. 
*, p<0.05. **, p<0.01. ***, p<0.001. 
 
Figure 3. SLC7A10 regulates lipid accumulation in adipocytes. 3T3-L1 preadipocytes were induced to differentiate 
into mature adipocytes and harvested every second day throughout differentiation. Cultured primary human adipose 
stromal cells (hASCs) were induced to differentiate into mature adipocytes and harvested every second or fourth day 
throughout differentiation. Lipid accumulation was measured by Oil-Red-O lipid staining.  
(A-D) mRNA expression of 3T3-L1 Slc7a10 was quantified by qPCR, relative to Rps13 expression (n=3). mRNA 
expression of SLC7A10 from hASC cultures was measured by combining the expression profiles of differentiating fat 
cells from two people were combined (n=2, donors 1 and 2), and quantified relative to HPRT mRNA expression. For 
western blotting, a representative expression profile is shown (n=2 replicates, for both 3T3-L1 and donor 3) and protein 
expression was calculated relative to HSP90. 20 and 30 µg protein were loaded per well for 3T3-L1 and hASCs 
respectively, and the following antibodies were used: HSP90 (1:1000, Cell Signaling, cat.no 4874), SLC7A10 (1:500, 
Santa Cruz Biotechnology, cat.no sc-292032); HRP goat anti-rabbit IgG (1:10000, Thermo Scientific, cat.no 3546); 
HRP goat anti-mouse IgG (1:7500, BD Biosciences, cat.no 554002). Data are presented as mean ± SD. 
(E-F) SLC7A10 inhibition throughout differentiation of 3T3-L1s (day 2-8) and hASC cultures (day 3-12) increased 
lipid accumulation as measured by Oil-Red-O lipid staining. SLC7A10 inhibitors 1 and 2 were used at a final 
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concentration of 10 µM. Data for 3T3-L1s and representative hASC cultures (n = 4, donors 4, 5, 6 and 7) are shown 
(n=3-6 replicate wells). Data are presented as mean ± SD. 
*, p<0.05. **, p<0.01. ***, p<0.001. 
 
Figure 4. SLC7A10 inhibition strongly affects genes related to energy metabolism in adipocytes.  
SLC7A10-associated gene expression patterns were analyzed in mature adipocytes isolated from SC adipose tissue 
(A) and in cultured primary human adipose stromal cells (hASCs) treated with DMSO or SLC7A10 inhibitor 1 from 
day 7-8 during adipogenic differentiation (B-C).  
(A) Mature adipocytes were isolated from biopsies of people with a BMI between 18 and 45 (n=24, ADIPO cohort). 
Global gene expression was profiled by Illumina microarrays. Genes across the genome that were co- or anti-expressed 
with SLC7A10 (Pearson’s correlation β > 0.65) were subjected to PANTHER gene ontology analysis. The biological 
processes most enriched with SLC7A10-correlated genes are shown, with indication of enrichment p-values by the 
color scale. 
(B-C) hASCs were obtained from abdominal SC adipose tissue (n=6, donors 8-13), differentiated for 8 days and 
treated with DMSO or SLC7A10 inhibitor 1 for 24 hours from day 7-8. Gene ontology terms were analyzed by 
PANTHER following RNA-sequencing. Up- and down-regulated pathways are shown here with enrichment 
visualized on the x-axis, while the number of genes found in each pathway is shown by the size of the circle. Relative 
gene expression between SLC7A10 inhibitor 1 and DMSO-treated hASCs is depicted for genes in the top up- and 
down-regulated pathways (C). Data are presented as mean ± SD. 
hASC, human adipose stromal cells 
*, p<0.05. **, p<0.01. ***, p<0.001. 
 
  
Figure 5. SLC7A10 stimulates adipocyte mitochondrial respiratory capacity. Human adipose stromal cells 
(hASCs) and 3T3-L1 preadipocytes were differentiated for 12 and 8 days respectively and treated for 2-24 hours prior 
to respiration measurements. Oxygen consumption rate (OCR) and respiratory capacity in live adipocytes were 
measured by the Seahorse XF Cell Mito Stress Test assay. OCR was measured under basal conditions and after 
sequential addition of the following compounds at indicated final concentrations; oligomycin (3 uM); Carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) (1.5 uM); rotenone (1 uM) and antimycin A (1 uM). Outliers 
were removed based on a Whisker Tukey test of the OCR data for each time point in each well, before basal respiration, 
ATP production, maximal respiration and spare respiratory capacity were calculated according to the manufacturer’s 
protocol. Results are presented as geometric mean ± 95% confidence interval (n=12-44 replicate wells in a 96-well 
plate). 
(A) hASCs (donor 14) were differentiated until day 11 and treated with DMSO or SLC7A10 inhibitor 1 for 2 or 24 
hours. 
(B) 3T3-L1 preadipocytes were differentiated until day 8, and treated with DMSO or SLC7A10 inhibitor 2 for 24 
hours from day 7-8 
(C) 3T3-L1 preadipocytes were induced to differentiate and transfected with an expression plasmid encoding Slc7a10 
or empty vector on day 2, 4 and 6, before analysis on day 8. 
hASC, human adipose stromal cells; OCR, oxygen consumption rate. 
*, p<0.05. **, p<0.01. ***, p<0.001. 
 
Figure 6. SLC7A10 regulates serine uptake, glutathione levels and redox state in adipocytes. Human adipose 
stromal cells (hASCs) from SC adipose tissue (n=6) and 3T3-L1 preadipocytes were cultured, differentiated and 
treated with DMSO or SLC7A10 inhibitors, or transfected with Slc7a10 expression plasmid. Total glutathione (GSH) 
levels were measured using a GSH probe coupled to a luciferase reaction (E-G). ROS generation was measured by a 
ROS probe detected by a laser plate reader (H-J) and lipid accumulation was measured by Oil Red O (K). Fluxes of 
small neutral amino acids in cultured hASCs in response to the selective SLC7A10 inhibitor 1 (10 µM) were assessed 
by measuring changes in medium concentrations by GC-MS /MS (A) and by radiometric assays (B).  
(A) Amino acid flux in cultured hASCs throughout adipogenic differentiation were assessed based on the amino acid 
concentrations in unconditioned medium and change in concentrations upon cell culture during 48-hour periods. Data 
for the mean of two replicate wells from a representative experiment is shown (donor 4). 
(B)  Cultured hASCs were washed three times in 37 °C sodium free assay buffer 120 mM choline chloride, 25 mM 
triethylammonium bicarbonate, 1.5 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 1.2 mM KH2PO4, 10 mM glucose, 10 
mM HEPES, 5.5 mM glucose, adjusted to pH 7.4 and sterile filtered), and treated with SLC7A10 inhibitor 1 for 30 
minutes. Unlabeled D-serine was added to designated wells (as positive control), before radioactive-labelled (1 µM) 
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3H-D-serine was added to all wells. Following incubation at 37 °C for 30 minutes, assays were stopped by placing 
cells on ice and washing three times with ice cold assay buffer. Cells were lysed and loaded in Ultima Gold fluid 
cartridges (Perkin Elmer) and isotope retention (counts per minute, CPM) in cell lysates was quantified using a Tri-
Carb 4910 TR scintillation counter (Perkin Elmer). CPM values were normalized to protein content in corresponding 
sample using DC protein assay (Bio-rad) (n=4-6, -donor 3). Data are presented as mean ± SD. 
(C) Summary figure of serine dependent processes and metabolic pathways modified from Newman and Maddocks 
(11). Serine is important for several metabolic pathways and processes, such as OXPHOS (oxidative phosphorylation) 
and is also a precursor for biosynthesis of molecules such as methyl groups, purines, and glutathione (GSH).  
(D) Gene expression measured by RNA-seq showed an enrichment of genes involved in the pentose phosphate shunt, 
NADPH regeneration and glutathione metabolic processes (n=6 individuals, donors 8-13). Data are presented as mean 
± SD. 
(E-F) 3T3-L1 preadipocytes and hASCs (donor 6) were induced to differentiate to day 8 and day 12, respectively. 
Total glutathione (GSH) following treatment with DMSO or SLC7A10 inhibitors 1 and 2 (10 µM) for 15 minutes or 
24 hours (3T3-L1s) and 45 minutes (hASCs) (n=10-22 replicate wells), by the GSH/GSSG-Glo Assay (Promega) 
which uses a GSH probe activated by a luciferase reaction. Data are presented as mean ± SD. 
(G) 3T3-L1 preadipocytes were induced to differentiate and transfected with Slc7a10 expression plasmid or empty 
vector on every second day of differentiation (days 2, 4 and 6). Total glutathione (GSH) was measured on day 8 as 
described above (n= 37-39). Data are presented as mean ± SD. 
(H-I) 3T3-L1 preadipocytes and hASCs (donors 16, 17) were induced to differentiate until day 8 and day 12 
respectively and treated with DMSO or SLC7A10 inhibitors 1 and 2 (10 µM) immediately before the assay. ROS 
generation was measured using the fluorescent probe CM-H2DCFDA (Thermo Fisher). Cells treated without ROS 
probe served as negative control. The time-course for a representative experiment is shown (donor 17), together with 
change in ROS generation from start to end (n=11 replicate wells in 96-well plates). Data are presented as mean ± SD. 
(J) 3T3-L1 preadipocytes were induced to differentiate and Slc7a10 was overexpressed (1µg/ml or 3µg/ml) for 48-
hours (day 6-8) using the transfection reagent TransIT-LT1 and additionally cells were treated with DMSO or 
SLC7A10 inhibitor 1 for 48-hours (day 6-8). ROS generation was measured on day 8 as described above. Change in 
ROS generation from start to end is shown here (n =). Data are presented as mean ± SD. 
(K) 3T3-L1 preadipocytes were induced to differentiate and treated with DMSO or SLC7A10 inhibitors 1 and 2 every 
second day during differentiation from day 2-8 with and without ROS scavenger N-acetyl-L-cysteine (10 mM) (Sigma 
Aldrich), and with and without insulin (1 µg/ml) from day 4-8. Lipid accumulation was measured by Oil-Red-O lipid 
staining (n=3). Data are presented as mean ± SD.  
GSH, glutathione; hASC, human adipose stromal cells, ROS, reactive oxygen species.  
*, p<0.05, **, p<0.01. ***, p<0.001 (comparing DMSO and SLC7A10 inhibitor without ROS scavenger Nac)  
§§§, p<0.05 (comparing with/without ROS scavenger Nac) 
 †, p<0.05, †††, p<0.001 (comparing DMSO and SLC7A10 inhibitor with ROS scavenger Nac) 
  
 
Figure 7. SLC7A10 inhibition decreases insulin-stimulated glucose uptake. Glucose uptake was assessed by 
radiometric assay in cultured 3T3-L1 preadipocytes (A) or hASCs (B) induced to differentiate for 8 and 12 days, 
respectively. 3T3-L1s were treated with DMSO or SLC7A10 inhibitors 1 and 2 (10 µM) for either 24 hours (day 2-8) 
or from day 2 to 8, and hASCs (donor 7) were treated with DMSO or SLC7A10 inhibitor 1 (10 µM) for 24 hours (day 
11-12). Insulin (final concentration 10 nM) was added 30 minutes prior to the assay, and deoxy-D-[14C]-Glucose was 
added for 30 minutes. Glucose uptake was measured using a scintillation counter (n=6 replicate wells in 12-well 
plates). Data are presented as mean ± SD.  
hASC, human adipose stromal cells. 





Supplementary Information includes seven figures and five tables, and can be found with this 
article online. 
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Supplementary Table 1. Primers used for qPCR. 
Gene Forward primer (5’ → 3’) Reverse primer (5’ → 3’) 
SLC7A10 Human CGCCCTCCCCAGTCC CCCGAGCCGATGATGTTC 
HPRT* Human TGACCTTGATTTATTTTGCATACC  CGAGCAAGACGTTCAGTCCT 
Slc7a10 Mouse CTTCTGGATGACACCGTCTG  GATGGCACGAGGTAGGTTCT 
Rps13* Mouse CAGGTCCGTTTTGTGACTG  AGCATCCTTATCCTTTCTGT 
* Reference gene 
 
Supplementary Table 2. Characteristics of donors of liposuction material for human primary 
adipose stromal cell (hASC) cultures. 
Donor no. Figure no. Age BMI 
1 3C 53 26.4 
2 3C 41 32.4 
3 3D, 6B 67 26 
4 3F, S7B 32 26.9 
5 3F, S7B 52 24.3 
6 3F, S7C 52 30 
7 3F, 6K 52 26.7 
8 4B-C, S2A-D, S5A-B, 6D 53 31.5 
9* 4B-C, S2A-D, S5A-B, 6D 36 24.3 
10 4B-C, S2A-D, S5A-B, 6D 21 29.4 
11 4B-C, S2A-D, S5A-B, 6D 58 28 
12 4B-C, S2A-D, S5A-B, 6D 45 28.4 
13 4B-C, S2A-D, S5A-B, 6D 45 30 
14 5A 32 25.5 
15 6A, S6A-B 48 27.7 
16 6H 46 24.3 
17 6H 32 28.4 
18 S6B 68 32.8 
* Male. 
 
Supplementary Table 3. Plasmids for overexpression. 
Vector name Description Manufacturer 
pCMV6-Kan/Neo mSlc7a10 (untagged) Origene 
pCMV6-XL4/XL5/XL6 TrueCloneTM Empty vector Origene 
 
 
Supplementary Table 4. mRNA expression and correlations for identified candidate genes with differential expression in human adipose tissue 
(Jersin et al. Diabetes) 
 Cohort: BPD-Fat (n=12) ADIPO (n=12) SibPair (n=88) 
  OM/SC Post/Pre OM mRNA SC mRNA WHR = α + β1SEX + β2BMI + β3GENE EXPRESSION + ε 
Symbol Probe ID mRNA ratio Whole Adipo SVF Whole Adipo SVF Probe ID SC mRNA R-square* p-value pos or neg 
Higher in OM vs. SC fat, up-regulated in SC fat after fat loss           
CIDEA ILMN_2390318 1.70 1.64 1 094 5 627 312 655 2 522 235 221295_at 155 0.520 0.0002 neg 
DFNA5 ILMN_1670145 1.77 1.96 920 835 2 344 385 478 1 552 203695_s_at 28.3 0.450 0.122 ns 
FLRT2 ILMN_1769615 1.63 1.90 565 255 1 696 313 407 841 204359_at 36.1 0.460 0.048 pos 
GAS1 ILMN_2062701 1.73 2.02 1 155 368 2 685 603 256 1 801 204457_s_at 194 0.478 0.010 pos 
GPD1L ILMN_1694106 1.65 1.77 2 049 4 647 2 421 1 193 1 607 1 974 212510_at 95.2 0.590 2.14x10-7 neg 
HOXA5 ILMN_1753613 2.38 2.11 1 418 4 692 4 448 800 2 797 2 819 213844_at 50.2 0.469 0.021 neg 
SLC7A10 ILMN_1681087 1.83 1.84 1 603 4 986 312 866 2 225 204 220868_s_at 20.5 0.510 0.001 neg 
                   
Higher in OM vs. SC fat, down-regulated in SC fat after fat loss           
ALDH1A2 ILMN_1748538 -1.54 2.48 1 686 464 5 459 505 215 814 207016_s_at 18.0 0.498 0.002 pos 
GFPT2 ILMN_1709674 -1.93 1.61 1 153 240 1 225 782 243 1 252 205100_at 12.4 0.443 0.247 ns 
PDLIM3 ILMN_2230025 -1.55 1.94 989 487 1 478 513 250 676 209621_s_at 7.9 0.448 0.150 ns 
TFPI2 ILMN_2068104 -1.52 1.94 577 221 694 269 178 223 209278_s_at 66.8 0.437 0.542 ns 
TMEM158 ILMN_1792455 -1.63 1.67 568 285 964 382 304 445 213338_at 2.8 0.472 0.016 pos 
                   
Lower in OM vs. SC fat, up-regulated in SC fat after fat loss            
APOC1 ILMN_1789007 3.21 -1.53 309 259 873 544 536 1 556 204416_x_at 50.0 0.445 0.191 ns 
COL6A3 ILMN_2307861 1.67 -1.54 3 342 3 154 15 450 5 519 3 276 23 271 201438_at 569 0.447 0.167 ns 
CTHRC1 ILMN_2117508 1.52 -2.01 306 154 378 747 180 1122 225681_at 103 0.465 0.029 pos 
CTSG ILMN_1680424 2.41 -1.64 576 181 2 799 1 135 220 7 428 205653_at 14.4 0.515 0.0003 pos 
DCLK1 ILMN_2165354 1.98 -1.56 418 396 1 465 696 471 3 725 229800_at 91.2 0.462 0.041 pos 
EMX2 ILMN_2187746 1.63 -1.54 151 175 183 239 443 634 221950_at 12.0 0.489 0.003 pos 
FNDC1 ILMN_2163873 3.60 -1.62 205 146 299 322 190 2 152 226930_at 13.6 0.443 0.246 ns 
PRRX1 ILMN_1739496 1.76 -2.23 1 112 707 4 367 2 266 1 014 11 052 226695_at 202 0.518 0.0002 pos 
SERPINA5 ILMN_1759910 1.52 -3.10 165 163 243 559 202 1925 209443_at 12.6 0.468 0.024 pos 
                   
Lower in OM vs. SC fat, down-regulated in SC fat after fat loss           
CCND1 ILMN_1688480 -1.62 -3.23 2 587 4 866 3 457 7 409 18 302 4 661 208712_at 124 0.471 0.017 pos 
DARC ILMN_1723684 -1.65 -1.55 2 191 1 169 2 456 3 381 666 3 742 208335_s_at 70.5 0.467 0.025 pos 
EGFL6 ILMN_2057479 -5.68 -6.95 351 355 711 3 039 15 392 1 146 219454_at 428 0.461 0.045 pos 
GPR56 ILMN_1697228 -2.11 -1.64 868 968 1 455 1 347 624 1 959 212070_at 74.7 0.436 0.563 ns 
IFIT3 ILMN_1664543 -1.55 -1.53 214 281 255 321 235 293 229450_at 91.5 0.462 0.040 pos 
INHBB ILMN_1685714 -1.80 -1.53 754 1 584 675 1 205 2 511 940 205258_at 75.5 0.478 0.010 pos 
ITIH5 ILMN_1731862 -1.60 -1.67 379 515 230 623 1 088 327 219064_at 457 0.486 0.005 pos 
MSC ILMN_1741404 -2.32 -1.72 341 599 274 578 968 312 209928_s_at 3.3 0.470 0.018 pos 
NOTCH3 ILMN_1658926 -1.51 -2.58 480 909 888 1 408 3 183 2 143 203238_s_at 16.5 0.479 0.009 pos 
PEMT ILMN_1745806 -1.51 -2.30 1 129 3 191 798 2 368 10 395 1 665 207621_s_at 138 0.486 0.004 pos 
RND3 ILMN_1759513 -3.83 -1.69 2 143 782 1 147 2 996 1 959 1 887 212724_at 83.4 0.469 0.020 pos 
SERPINA3 ILMN_1788874 -1.83 -1.66 367 211 624 602 325 1 007 202376_at 4.8 0.457 0.063 ns 
SNCG ILMN_1653161 -2.01 -1.63 566 1 163 327 975 3 253 396 209877_at 18.2 0.440 0.334 ns 
SOX7 ILMN_2134056 -3.14 -1.82 495 208 214 764 174 258 228698_at 93.1 0.467 0.024 neg 
TNFRSF4 ILMN_2112256 -1.94 -1.55 348 346 470 518 270 541 214228_x_at 6.0 0.454 0.085 ns 
TUBB2A ILMN_2044813 -2.51 -1.82 590 867 325 1 101 2 276 516 204141_at 588 0.492 0.003 pos 
UPP1 ILMN_1746837 -2.18 -1.50 1 264 506 772 1 749 640 1 214 203234_at 12.3 0.492 0.003 pos 
               
Adipo, isolated adipocyte fraction; neg, negative correlation; ns, non-significant; OM, omental adipose tissue; pos, positive correlation; Pre, samples obtained 
before bariatric surgery; Post, samples obtained one year after bariatric surgery; SC, subcutaneous adipose tissue; SVF, stromal vascular fraction; Whole, whole 
adipose tissue.  
       
  
Supplementary Table 5. mRNA co-expression with SLC7A10/ASC-1 mRNA in 
human adipocytes from the ADIPO cohort (12 lean, 12 obese) (Jersin et al. Diabetes)   
SYMBOL Coeff. SYMBOL Coeff. SYMBOL Coeff. SYMBOL Coeff. 
SLC7A10 1 continued  continued  continued  
UTX 0.909 CCNH 0.766 PHYH 0.734 DNAJA3 0.715 
BCKDHB 0.895 PPP1R16A 0.766 RAPGEF4 0.734 GSDMB 0.715 
AK3L1 0.850 ACOT1 0.764 (undefined) 0.733 HIBADH 0.714 
TMEM22 0.839 MLYCD 0.763 MED26 0.733 CD40 0.714 
RPL34 0.836 TP53I13 0.763 HIGD2A 0.733 TMEM69 0.713 
LGALS12 0.830 UBTD1 0.760 C7orf26 0.733 LACTB2 0.713 
BRP44L 0.826 CMTM7 0.760 ABCC9 0.732 MRPL46 0.713 
COX7C 0.822 CCBL2 0.758 LOC731007 0.731 SOX6 0.713 
CHL1 0.822 FAM73B 0.758 POLS 0.731 GSDMB 0.712 
MCCC1 0.822 CKB 0.757 PIGP 0.730 D2HGDH 0.710 
DHTKD1 0.821 MRPS11 0.756 C14orf2 0.730 FGFRL1 0.710 
AGT 0.820 MOSC2 0.755 DTNA 0.730 PPP1R1B 0.710 
SDHB 0.818 PCCA 0.755 LETMD1 0.730 ZFHX4 0.710 
ACADM 0.817 COX5A 0.755 TFAM 0.729 RHOT1 0.708 
NDUFB5 0.812 RTCD1 0.755 MRPS34 0.729 (undefined) 0.708 
MOSC1 0.808 CYC1 0.755 (undefined) 0.729 NAALAD2 0.708 
COQ9 0.808 FLJ23834 0.754 CSNK2A1 0.728 TXNDC12 0.707 
C7orf30 0.803 AQP7P2 0.754 CICE 0.728 FABP5 0.707 
ATL2 0.802 RTN3 0.753 DTNA 0.728 LOC653145 0.707 
C6orf66 0.798 LOC648605 0.753 (undefined) 0.727 SNX5 0.706 
C17orf95 0.795 ZFPM1 0.753 (undefined) 0.727 PCBD1 0.706 
ELOVL3 0.795 (undefined) 0.752 MRPL21 0.725 TSPAN13 0.706 
VPS54 0.789 MCAT 0.750 HAX1 0.724 ORMDL3 0.705 
ALDH1L1 0.789 LOC652837 0.749 CMC1 0.723 CNIH 0.705 
DDT 0.789 CAMK1 0.749 LOC653479 0.723 CCT7 0.704 
UBE2W 0.788 GART 0.748 UCKL1 0.723 PATL1 0.703 
UQCRFS1 0.788 XRN1 0.748 SLC25A4 0.722 ARIH1 0.703 
BTF3L4 0.784 THYN1 0.747 LDHD 0.722 CLPP 0.703 
ANO6 0.784 COX5B 0.746 C12orf45 0.722 CASD1 0.702 
RDH10 0.783 PXMP2 0.746 DMRT2 0.721 C4orf14 0.702 
UQCRH 0.783 POLR1D 0.745 PXMP2 0.720 AUH 0.701 
LOC646345 0.780 LOC648695 0.745 SH3GLB1 0.720 BCKDHB 0.701 
C7orf44 0.780 AK3L1 0.743 C2orf56 0.719 RFXANK 0.701 
PCK1 0.776 FAM18B 0.743 FAM152B 0.718 SCO1 0.701 
ATP5F1 0.776 SLC2A1 0.742 PCGF6 0.718 LOC650494 0.701 
HSPD1 0.775 HIST1H2BD 0.742 CCNF 0.718 LOC643300 0.700 
KIAA1191 0.773 C21orf70 0.741 EXOSC3 0.718 GOT1 0.700 
ACAD8 0.772 AK2 0.741 ALKBH1 0.718 SYPL1 0.700 
ESRRA 0.771 CDH23 0.739 PCBD1 0.717 DCI 0.699 
ABHD3 0.771 CYB5A 0.738 BPHL 0.717 MCCC2 0.699 
SLC25A5 0.770 C21orf33 0.738 SLC25A40 0.716 ACOT2 0.699 
MRPL41 0.770 CS 0.737 ATP1B3 0.716 (undefined) 0.699 
ELK1 0.769 ENDOG 0.737 FBXO21 0.715 STOX1 0.698 
TMLHE 0.767 BCKDHB 0.736 MRPS22 0.715 FRMD4A 0.698 
C2orf47 0.767 MRPL33 0.735 ZNF280D 0.715 WDR43 0.698 
SYMBOL Coeff. SYMBOL Coeff. SYMBOL Coeff. SYMBOL Coeff. 
continued  continued  continued  continued  
RPAIN 0.698 CALML4 0.687 TMCO6 0.674 MACROD1 0.660 
MTFMT 0.698 RDH14 0.687 SEC24B 0.674 CA2 0.659 
SLC4A4 0.698 TAF1L 0.686 (undefined) 0.674 GTF2IRD1 0.659 
DTNA 0.698 DDX47 0.685 PRIM1 0.674 C17orf61 0.658 
ANKRD11 0.697 CDKN2C 0.685 LETMD1 0.673 FBXO46 0.658 
QPCT 0.697 THYN1 0.684 GBE1 0.673 HSCB 0.658 
FGFRL1 0.696 SDHA 0.682 TYSND1 0.673 NDUFV2 0.658 
MRPL39 0.696 SNORD100 0.682 EBAG9 0.672 LOC643466 0.657 
VPS26B 0.696 SUMO2 0.682 MRPS23 0.671 NDUFB11 0.656 
KIAA0261 0.696 KLF15 0.682 TMLHE 0.671 MGC70857 0.656 
GCHFR 0.695 HSD17B10 0.681 MESP1 0.671 (undefined) 0.656 
C1orf66 0.695 GNAQ 0.681 CPEB2 0.671 NDUFV3 0.655 
SPTB 0.695 CMTM7 0.681 MKNK2 0.670 PMPCB 0.655 
STRADB 0.695 RABGGTB 0.681 (undefined) 0.670 (undefined) 0.655 
VPRBP 0.694 GGCT 0.681 ALDH6A1 0.670 VPS35 0.655 
PLAGL2 0.694 SLC3A2 0.681 FBXO28 0.669 LPIN1 0.655 
SLC16A7 0.694 CNBP 0.680 C2orf56 0.669 AASDHPPT 0.655 
ACADL 0.694 RSBN1 0.680 AGPAT2 0.669 LOC642335 0.655 
NDUFB6 0.694 RBMS2 0.680 PPARG 0.669 NPC1 0.654 
CRLS1 0.694 SCP2 0.680 PIGP 0.668 SLC2A4 0.654 
BDH1 0.693 (undefined) 0.680 STK35 0.668 RAVER1 0.654 
SPRYD4 0.693 LOC284023 0.679 MAD2L1BP 0.668 DAP3 0.654 
ACADM 0.693 (undefined) 0.679 CMTM7 0.667 L2HGDH 0.653 
ACP1 0.693 ALKBH1 0.679 INTS6 0.667 MAZ 0.653 
NCOR2 0.693 ZNF280D 0.679 SOSTDC1 0.666 FMO5 0.653 
COX6A1 0.693 SCN3A 0.678 LIX1L 0.665 EIF3M 0.653 
MRPS2 0.692 C17orf95 0.678 PIK3CB 0.665 SEC11A 0.653 
C9orf72 0.692 (undefined) 0.678 CS 0.664 (undefined) 0.653 
GFPT1 0.692 CNIH 0.678 AQP7 0.664 PCNX 0.652 
MLX 0.692 CA2 0.678 ANKRD9 0.664 YPEL5 0.652 
SNURF 0.692 SEPHS1 0.678 PDZD7 0.664 NDFIP2 0.652 
BLOC1S1 0.691 ESRRAP2 0.677 ATAD2 0.663 NAT5 0.652 
PAXIP1 0.691 LOC729317 0.677 SFXN2 0.663 (undefined) 0.652 
UTP18 0.691 (undefined) 0.677 MEIS2 0.663 HYLS1 0.652 
C18orf8 0.690 NET1 0.677 GTPBP3 0.663 RPL35A 0.652 
GLRX2 0.690 MCM7 0.677 RAB40C 0.663 STOX1 0.651 
LOC652545 0.690 DUSP4 0.677 TBP 0.663 STAMBP 0.651 
GRPEL1 0.690 ICAM3 0.676 CLK2 0.663 DHPS 0.651 
CCNC 0.689 DNAH1 0.676 SEC24B 0.662 STBD1 0.650 
TRPT1 0.689 CSNK2A2 0.676 NDUFAF2 0.662 FBXO44 0.650 
PATZ1 0.689 LOC285074 0.676 HINT3 0.662 OXA1L 0.650 
SLC25A22 0.689 C16orf14 0.676 LOC645436 0.662 (undefined) 0.650 
PC 0.689 RPL9 0.675 PPP2R2D 0.662 ACY1 0.650 
SMARCD1 0.688 (undefined) 0.675 (undefined) 0.661   
UBQLN1 0.688 KIAA0367 0.675 PLCXD1 0.660   
CASZ1 0.688 C1QL2 0.675 TCF12 0.660   
LDLRAD1 0.688 PCCB 0.675 ZNF512B 0.660   
CXorf15 0.687 POLE 0.674 MIA3 0.660   
 Coeff. SYMBOL Coeff. SYMBOL Coeff. SYMBOL Coeff. 
SYMBOL 
(undefined) -0.650 continued  continued  continued  
IFT57 -0.651 CANX -0.676 SETBP1 -0.703 TLN1 -0.769 
OLFML1 -0.651 ITGA11 -0.676 DAB2 -0.704 CCNYL1 -0.769 
TFPI -0.652 CPD -0.677 ZYX -0.705 RAP2A -0.771 
C5orf5 -0.652 LAPTM5 -0.677 SOX4 -0.705 FBLN2 -0.775 
ST5 -0.653 ANXA11 -0.677 EMX2 -0.705 RUFY3 -0.781 
COL6A2 -0.653 FAM129A -0.677 C21orf51 -0.705 TMSB10 -0.786 
CCDC25 -0.654 AP1S2 -0.677 ACTG1 -0.707 IQSEC2 -0.787 
HABP4 -0.655 THBS2 -0.678 ZNF219 -0.709 PTTG2 -0.793 
CILP -0.655 ARHGAP28 -0.678 COL4A5 -0.711 MGP -0.845 
LOC648470 -0.655 FBLN5 -0.678 PDLIM7 -0.711 RANBP3L -0.846 
PDCL3 -0.657 SLC7A2 -0.679 RNASEL -0.711   
(undefined) -0.657 MYO1B -0.680 MAP1B -0.713   
KIAA1160 -0.657 C1orf24 -0.681 STX2 -0.714   
KCTD12 -0.658 MTTP -0.681 PSAP -0.716   
LOC651302 -0.659 SPARC -0.681 ANKS1B -0.717   
TMEM119 -0.659 CALM3 -0.684 DKK3 -0.719   
LUM -0.660 CDH11 -0.684 RCN1 -0.720   
ITIH5 -0.661 ACTB -0.685 SPON2 -0.723   
TRPV2 -0.661 CAPZB -0.685 DGKI -0.724   
LOC390956 -0.661 (undefined) -0.685 CAPNS1 -0.726   
CLN5 -0.662 LOC389958 -0.686 SLC2A12 -0.726   
ACTN4 -0.662 REEP5 -0.688 SAP18 -0.727   
(undefined) -0.663 CCDC105 -0.688 RNASEL -0.732   
LMOD1 -0.663 ACTB -0.689 LOX -0.735   
IFITM5 -0.663 DAAM2 -0.689 MYO1D -0.738   
(undefined) -0.663 SLC39A3 -0.689 SH3BGRL2 -0.741   
(undefined) -0.664 CCBP2 -0.690 CDC26 -0.741   
FLJ22374 -0.665 ARHGAP21 -0.691 MED20 -0.742   
BICD2 -0.666 VWA1 -0.693 KIAA1598 -0.742   
NEXN -0.666 COL4A5 -0.694 TAX1BP3 -0.743   
CLEC3B -0.668 LPAR1 -0.694 DPT -0.748   
(undefined) -0.668 CNN3 -0.696 TMEM98 -0.748   
SRI -0.669 INHBB -0.698 MGP -0.749   
PON2 -0.669 DCTN1 -0.699 EMX2 -0.751   
CYLN2 -0.671 CXCL12 -0.700 ABHD4 -0.754   
CETN2 -0.673 CCND2 -0.701 DRAM -0.756   
LOC391013 -0.673 PFKP -0.701 ITGA11 -0.757   
CANX -0.675 CAMK1D -0.702 (undefined) -0.766   
ITGB5 -0.675 ASCC3 -0.702 ITGB1 -0.768   
 






Supplementary Figure 1. Correlations of SLC7A10 mRNA expression with insulin resistance and adiposity 
traits in the RIKEN (n=58, panel A) and Sib Pair-Subgroup (n=24, panel B) cohorts. 
SLC7A10 mRNA expression was retrieved from microarray expression analyses (Affymetrix) and Spearman 






Supplementary Figure 2. Effects of SLC7A10 inhibition on global gene expression measured by RNA-
sequencing in human primary adipocytes. 
Human adipose stromal cell (hASC) cultures were obtained from abdominal subcutaneous adipose tissue (n=6), 
differentiated for 8 days, and treated with DMSO or SLC7A10 inhibitor 1 for 24 hours from day 7-8. Global gene 
expression was measured by RNA-seq, where sample reads were mapped against the Human genome (GrCH38) 
using HiSat (Version 2.1.0), with options –t “exon” and –g “gene_id” to summarize count values from individual 
exons into genes, resulting in a matrix of raw counts. Aligned reads were then put into featureCounts (Version 
1.5.2) with default options, resulting in a matrix of raw counts. Data were normalized and differential expression 
analysis was performed utilizing DESeq2 (Version 1.22.2). Pathway analysis of RNA sequencing data was 
performed using PANTHER classification system (PANTHER v.14.0). Differentially expressed genes identified 
with a FDR cut-off (p<0.05) were used as input and Fischer’s exact test was used to identify statistically over/under 
represented pathways with a FDR cut-off (p<0.05) (1). Significant ontologies were visualized using ggplot2 
package (Version 3.1.0).  
 
(A-B) Principal component (PC) analysis of samples in DMSO and SLC7A10 inhibitor 1 treated groups are shown 
in (A) unadjusted and (B) adjusted for patient. 
 
(C) Volcano plot of differentially expressed genes between DMSO and SLC7A10 inhibitor 1 treatments. x-axis 
corresponds to log2 fold change (log2FC) and y-axis corresponds to -log10 (P-value). Red dots represent the 
transcripts with an absolute log2FC > 0.5 and P-value < 10E-10; green dots represent the transcripts with an 
absolute log2FC > 0.5; blue dots represent transcripts with P-value < 10E-10; grey dots represent transcripts which 
do not pass above thresholds. 
 
(D) Enrichment plot representing up-regulated and down-regulated biological processes between DMSO and 
SLC7A10 inhibitor treatments. Top 30 biological processes with an FDR-corrected P-value < 0.05 and fold 
enrichment ≥ 8 (arbitrary threshold for the sake of visual representation) are reported here. Gene Ontology (GO) 





Supplementary Figure 3. Confirmation of Slc7a10b loss-of-function mutation and outlier detection by RNA-
sequencing of zebrafish visceral adipose tissue. 
Mature (four-month old) wildtype (WT) and Slc7a10b mutant male zebrafish were fed 50-100% more than their 
regular feed for eight weeks. Visceral adipose tissue from three zebrafish housed in the same tank during the 
overfeeding was pooled. RNA was isolated and RNA-seq was performed. Sample reads were mapped against the 
Zebrafish genome (GRCz10) using HiSat (Version 2.05), matrixed in featureCounts (Version 1.5.2) and analyzed 
using DESeq2 (version 1.22.1). 
 
(A) Integrative genomics viewer (IGV) read visualization of each Zebrafish sample at the target site, with the 
A→T splice site mutation sa15382 highlighted in green.  
(B) Visualized expression values (RPKM) of average Slc7a10a and Slc7a10b expression in both WTs and mutants.  
(C) Outlier removal of anomalous RNA-Seq sequence reads (by sample) was performed by generating 
multidimensional scaling plots of distances between digital gene expression profiles. The samples mutant-A9 and 
WT-A2 were visually identified in the top graph as being erroneous due to their spread from the main cluster in 
the first dimension. The lower graph displays the distances after the removal of the first two outliers, showing WT-
A7 spreading from the main cluster. 
(D) The differential expression in WT-A7 was further investigated by utilizing the ontology gene expression 
profiles of the WT samples, and we observed that this sample differed significantly from other wild-types in the 
expression profile of stress-induced genes identified in human adipose tissue, warranting removal of WT-A7 from 
further downstream analysis. The stress-induced genes were identified by microarray analysis of omental human 
adipose tissue biopsies of non-obese patients. Omental biopsies from four patients were either frozen immediately 
or ~1 hour after surgical excision. The 1-hour delayed freezing induced a large array of immediate-early stress-
responsive genes including IL8 (induced already after 10 minutes) [24], largely recapitulating differences we 
previously observed between lean and extremely obese patients [153] (data not shown). We concluded that the 
WT-A7 sample was acutely stressed either in vivo or ex vivo, and that its inclusion in our initial analysis was 
entirely responsible for an apparent down-regulation of stress-responsive/inflammatory genes in the mutant 
compared to WT zebrafish. WT-A7 was therefore removed from further analysis, to avoid a dominating artefactual 




Supplementary Figure 4. Slc7A10b loss-of-function mutation in overfed zebrafish upregulates genes 
involved in urate, purine, and lipid metabolic processes. 
Mature (four-month old) wildtype (WT) and Slc7a10b loss-of-function male zebrafish were fed 50-100% more 
than their regular feed for eight weeks. Visceral adipose tissue from three zebrafish housed in the same tank 
during the overfeeding was pooled. RNA was isolated and RNA-seq was performed. Sample reads were mapped 
against the Zebrafish genome (GRCz10) using HiSat (Version 2.05), matrixed in featureCounts (Version 1.5.2) 
and analyzed using DESeq2 (version 1.22.1). 
 
(A) Volcano plot of differentially expressed genes between WT and Slc7a10b loss-of-function zebrafish. x-axis 
corresponds to log2 fold change (log2FC) and y-axis corresponds to -log10 (P-value). The red dots represent the 
transcripts with an absolute log2FC > 0.5 and P-value < 10E-10; green dots represent the transcripts with an 
absolute log2FC > 0.5; blue dots represent transcripts with P-value < 10E-10; grey dots represent transcripts which 
do not pass above thresholds. 
(B) Combined differentially expressed genes between Slc7a10b zebrafish WT and mutant into a single ranked list 
based on fold change, and gene ontology (GO) terms were analyzed using GOrilla (2). Enrichment plot 
representing up-regulated biological processes between WT and Slc7a10b loss-of-function zebrafish was 
visualized using the R package ggplot2. Biological processes with a P-value < 0.05 and fold enrichment ≥ 8 





Supplementary Figure 5. SLC7A10 impairment affects genes related to lipid- and energy metabolism in 
zebrafish adipose tissue and human primary adipocyte cultures. 
RNA-sequencing was performed as described in Supplementary Figures 2 and 4. For each dataset, genes were 
sorted based on fold change into a single ranked list, and analyzed using GOrilla to identify enriched ontologies 
(2). Significant ontologies were summarized for plotting utilizing the REViGO web package, which clusters 
representative ontologies via semantic similarity (3). RPKM values for gene expression visualizations were 
generated using edgeR (Version 3.16.5).  Overlapping ontologies between zebrafish adipose tissue and human 
adipose cultures were plotted using ggplot2 (Version 3.1.0). 
 
(A) Gene ontologies enriched with differentially expressed genes identified in RNA-seq from both zebrafish 
mutant and SLC7A10 inhibitor treated human adipocytes compared to control. Differentially expressed genes were 
combined into a single ranked list based on fold change using GOrilla analysis (2). Enriched ontologies in both 
the zebrafish mutant and SLC7A10 inhibitor 1 RNA-seq were aggregated, filtered by enrichment and significance, 
and plotted by relative enrichment. Overlapping ontologies between Zebrafish and SLC7A10 inhibitor 1 RNA-seq 
were visualized using the R package ggplot2 (Version 3.1.0). 
 
(B) Fold changes for up- and down-regulated genes in RNA-seq from both zebrafish mutant and SLC7A10 
inhibitor 1 treated (10 µM) human adipocytes compared to control. Outliers were removed using Whiskers Tukey 






Supplementary Figure 6. SLC7A10 inhibition affects mitochondrial respiration in cultured mouse 
adipocytes. 
3T3-L1s were differentiated and treated with SLC7A10 inhibitor 1 for either 2 or 24 hours, or Slc7a10 was 
overexpressed every second day from day 2-8.  
(A) OCR was measured at day 8 of differentiation under basal conditions and after sequential addition of the 
following compounds at indicated final concentrations; oligomycin (3 µM); FCCP (1.5 µM); rotenone (1 µM) and 
antimycin A (1 µM).  
(B) Outliers were removed based on a Whisker Tukey test of the OCR data for each time point in each well, before 
calculation of basal respiration, ATP production, maximal respiration and spare respiratory capacity according to 
the manufacturer’s protocol. Results are presented as geometric mean ± 95% confidence interval (n=22-24 
replicate wells in a 96-well plate). 
(C) 3T3-L1 preadipocytes were induced to differentiate and transfected with Slc7a10 expression plasmid or empty 
vector on every second day of differentiation (days 2, 4 and 6) and mRNA was collected on day 8. Slc7a10 
expression was quantified by qPCR relative to Rsp13 expression (n=3) 





Supplementary Figure 7. Inhibition of SLC7A10 in human primary and mouse adipocytes regulates 
adipocyte serine uptake and redox status. 
(A) Changes in alanine, threonine and glycine flux was not alter for hASCs treated with SLC7A10 inhibitor 1 
throughout differentiation. Amino acid flux was calculated based on the amino acid concentrations in 
unconditioned medium and change in concentrations upon cell culture during 48-hour periods. Data for two 
replicate wells for a representative experiment are shown. 
 
(B) The average reduction in serine influx due to SLC7A10 inhibition was calculated (as in A) for fully 
differentiated hASCs (day 10-12), for replicate experiments in cells from four different people. 
(C) hASCs were treated with SLC7A10 inhibitor 1 for 30 minutes at day 8 of differentiation. Thereafter, 
radiolabeled 3H-D-serine (1 µM) or 14C-L-serine (1 µM) was added for 30 minutes and cellular uptake of the 
radiolabeled amino acids was measured in cell lysate. Unlabeled D-serine and L-serine (100 mM) were used as 
positive control of uptake inhibition. Data are presented as mean ± SD (n=3-6). 
(D) 3T3-L1s were treated with SLC7A10 inhibitor 2 for 30 minutes at day 8 of differentiation. Thereafter, 
radiolabeled 14C-L-serine (1 µM) was added for 30 minutes and cellular uptake of the radiolabeled amino acids 
was measured in cell lysate. Unlabeled L-serine (100 mM) were used as positive control of uptake inhibition. Data 
are presented as mean ± SD (n=6). 
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